Related Experiment Video
Updated: Jun 16, 2025

A Modified Lean and Release Technique to Emphasize Response Inhibition and Action Selection in Reactive Balance
Published on: March 19, 2020
Falls in people with Alzheimer's disease: Exploring the role of inhibitory control
Marlee Wells1, Jane Alty2, Mark R Hinder3
1Wicking Dementia Research and Education Centre, College of Health and Medicine, University of Tasmania, Australia.
Abstract:
On average, people with dementia fall more often than their age-matched peers, with serious consequences, yet the underlying reasons remain poorly understood. This narrative review explores relevant psychological, physiological and neuroimaging studies to discuss whether diminished inhibitory control contributes to poor balance and falls in people with Alzheimer's Disease (AD), the most common form of dementia. Inhibitory control, a component of executive function, plays a vital role in suppressing dominant impulses or actions and regulating attention in favour of a desired outcome. Although objective tests of inhibitory control are not routinely used in clinical settings, research suggests inhibitory control declines early, and progressively, in AD. Postural tasks that require inhibitory control can improve the accuracy of distinguishing fallers from non-fallers beyond known factors. Neuroimaging studies link the prefrontal cortex to both inhibitory and postural control, and this region exhibits neuronal loss early in AD. Thus, emerging evidence suggests that accurately assessing inhibitory control could not only improve falls risk predictions but also aid AD detection.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment
Neural Regulation
Role of Cerebellum and Prefrontal Cortex in Memory
Role of Neurotransmitters in Memory
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

